Personalized or N-of-1 genomic therapies are opening new possibilities for treating patients with rare genetic conditions by making it increasingly possible to identify a patient’s specific disease-causing variant and rapidly design a therapy tailored to that individual.
Join the National Academy of Medicine on October 28, 2026 for an in-person conversation in Washington, D.C., bringing together science, technology, and policy professionals to explore the emerging science and real-world development of personalized genomic therapies, as well as:
- Lessons from recent efforts
- Ethical and practical questions raised by their development and delivery, and
- What it would take to create more sustainable and accessible pathways for highly individualized treatments
Agenda:
- Breakfast & Networking
- Developments in Personalized Genomic Therapies by Kiran Musunuru, MD, PhD, MPH, ML, MRA, Barry J. Gertz Professor for Translational Medicine, University of Pennsylvania Perelman School of Medicine
- Reflection on Responsible Innovation and Governance for Genomic Therapies by Hadley Stevens Smith, PhD, MPSA, Assistant Professor of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute
- Discussion moderated by Carrie Wolinetz, PhD, Senior Principal and Chair, Health Bioscience Innovations Practice, Lewis-Burke Associates.
- Informal Discussion and Networking
Bagels and Biotech is an initiative of the NAM Action Collaborative on Translating Emerging Science, Technology, and Innovation in collaboration with the National Academies Programs on Biomedical and Health Sciences & Life Sciences and Biotechnology. View all events in the discussion series.
